Univariate comparisons for patients with multiple myeloma: overall survival and progression-free survival rates
Prognostic factors at time of transplantation . | Overall survival . | Progression-free survival . | ||||
---|---|---|---|---|---|---|
Relative risk . | 95% CI . | P . | Relative risk . | 95% CI . | P . | |
Abnormal | ||||||
cytogenetics vs normal | .39 | .23-.68 | .001 | .44 | .27-.70 | < .0007 |
Age > 50 y vs < 50 y | 1.03 | .6-1.8 | .91 | 1.04 | .65-1.67 | .86 |
ALC ≥ 500 cells/μL vs < 500 cells/μL | .24 | .14-.42 | < .0001 | .34 | .21-.55 | < .0001 |
ANC ≥ 500 cells/μL vs < 500 cells/μL | .40 | .12-1.33 | .14 | .37 | .13-1.04 | .06 |
β2M > 2.7 mg/L vs ≤ 2.7 mg/L | .58 | .33-1.01 | .054 | .7 | .44-1.11 | .13 |
Bone marrow | ||||||
plasma cells ≥ 40% vs < 40% | .49 | .3-.8 | .007 | .55 | .35-.87 | .01 |
Circulating plasma cells | .39 | .23-.68 | .0007 | .46 | .28-.77 | .003 |
CRP > 0.8 mg/dL vs ≤ 0.8 mg/dL | .57 | .31-1.04 | .067 | .65 | .38-1.1 | .11 |
LDH level normal for age/sex vs > normal | .45 | .21-.95 | .037 | .45 | .24-.86 | .015 |
PCLI ≥ 1% vs < 1% | .34 | .2-.6 | .0001 | .34 | .21-.55 | < .0001 |
Platelet level > 20 × 109/L vs ≤ 20 × 109/L | .18 | .09-.36 | < .0001 | .3 | .16-.57 | .00024 |
No. pretransplant chemotherapy regimens | 1.58 | 1.05-2.38 | .028 | 1.7 | 1.18-2.44 | .004 |
Primary refractory | ||||||
disease vs plateau/response | NA3-150 | 2.94 | .63-13.7 | .17 | ||
Relapse off | ||||||
therapy vs plateau/response | 1.163-151 | .5-2.7 | .73 | 5.99 | 1.43-25.1 | .014 |
Relapse on | ||||||
therapy vs plateau/response | 3.083-151 | 1.4-6.76 | .005 | 13.94 | 3.3-58.5 | .0003 |
Stem cell source | ||||||
PBSCs vs BM | .45 | .26-.78 | .004 | .48 | .29-.79 | .004 |
Prognostic factors at time of transplantation . | Overall survival . | Progression-free survival . | ||||
---|---|---|---|---|---|---|
Relative risk . | 95% CI . | P . | Relative risk . | 95% CI . | P . | |
Abnormal | ||||||
cytogenetics vs normal | .39 | .23-.68 | .001 | .44 | .27-.70 | < .0007 |
Age > 50 y vs < 50 y | 1.03 | .6-1.8 | .91 | 1.04 | .65-1.67 | .86 |
ALC ≥ 500 cells/μL vs < 500 cells/μL | .24 | .14-.42 | < .0001 | .34 | .21-.55 | < .0001 |
ANC ≥ 500 cells/μL vs < 500 cells/μL | .40 | .12-1.33 | .14 | .37 | .13-1.04 | .06 |
β2M > 2.7 mg/L vs ≤ 2.7 mg/L | .58 | .33-1.01 | .054 | .7 | .44-1.11 | .13 |
Bone marrow | ||||||
plasma cells ≥ 40% vs < 40% | .49 | .3-.8 | .007 | .55 | .35-.87 | .01 |
Circulating plasma cells | .39 | .23-.68 | .0007 | .46 | .28-.77 | .003 |
CRP > 0.8 mg/dL vs ≤ 0.8 mg/dL | .57 | .31-1.04 | .067 | .65 | .38-1.1 | .11 |
LDH level normal for age/sex vs > normal | .45 | .21-.95 | .037 | .45 | .24-.86 | .015 |
PCLI ≥ 1% vs < 1% | .34 | .2-.6 | .0001 | .34 | .21-.55 | < .0001 |
Platelet level > 20 × 109/L vs ≤ 20 × 109/L | .18 | .09-.36 | < .0001 | .3 | .16-.57 | .00024 |
No. pretransplant chemotherapy regimens | 1.58 | 1.05-2.38 | .028 | 1.7 | 1.18-2.44 | .004 |
Primary refractory | ||||||
disease vs plateau/response | NA3-150 | 2.94 | .63-13.7 | .17 | ||
Relapse off | ||||||
therapy vs plateau/response | 1.163-151 | .5-2.7 | .73 | 5.99 | 1.43-25.1 | .014 |
Relapse on | ||||||
therapy vs plateau/response | 3.083-151 | 1.4-6.76 | .005 | 13.94 | 3.3-58.5 | .0003 |
Stem cell source | ||||||
PBSCs vs BM | .45 | .26-.78 | .004 | .48 | .29-.79 | .004 |